Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its application for marketing approval of Semaglutide Injection, a treatment for type 2 diabetes, has been accepted by China’s National Medical Products Administration. This product, developed by its subsidiary CSPC Baike, shows significant clinical advantages in glycemic control and safety compared to existing treatments. The company is also conducting trials for its use in treating obesity, indicating a strategic expansion in its product offerings to benefit a broader patient base.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company involved in the pharmaceutical industry, focusing on the development and production of innovative drugs. Its primary products include biopharmaceuticals and chemical drugs, with a market focus on addressing major health conditions such as diabetes and obesity.
Average Trading Volume: 213,100,438
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.8B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.